The famous biotech stock Delcath Systems, Inc. (NASDAQ:DCTH) failed to maintain its gains recorded earlier in the week. Recently the company reported that assessment from two institutions demonstrates strong tumor response, and overall survival potential of investigational PHP therapy. The subjects who responded to therapy, overall survival was estimated to be over three years.
The findings were released at the Regional Cancer Therapies International Symposium in a presentation. This analysis was planned by sides from Moffitt Cancer Center and the University Hospital Southampton. The presentation was headed by Dr. Alexandra Gangi. The biotech stock firm reported that the trial assessed outcomes of 49 subjects administered between 2008 and 2016 with HDS/ Melphalan at either the University Hospital Southampton or the Moffitt Cancer Center.
Subjects underwent as much as 115 PHP therapies. The median count of treatments per subject was 2, with patients getting one-to-six treatments. PHP therapy is a minimally invasive course that isolates the liver from the circulatory system, for high dose of chemotherapy may be given directly into the liver. Thereafter, blood is filtered from the liver to eliminate the chemotherapeutic agent thus reducing systemic exposure.
Dr. Jennifer K. Simpson, the CEO and President of Delcath, reported that subjects suffering with metastatic ocular melanoma have an average of six to eight months of survival. The retrospective analysis confirmed a much longer survival after HDS/ Melphalan, and presented an interesting long-term view at patient outcomes after cure with Melphalan/HDS.
This estimated 1,207 days median OS and 657-day median OS in those with a complete or partial response is impressive, and they consider speaks to the prospective of the system to offer meaningful durable response.
PHP with HDS/ Melphalan was advanced by Delcath as a whole organ treatment for the liver. It is available in device form in Europe by name CHEMOSAT®.